Skip to main content

COVID 19 Updates from RheumNow

Telehealth Diet and Exercise Benefits Knee Osteoarthritis

Annals of Internal Medicine has reported the results of a randomized clinical trial showing that telehealth-delivered exercise and diet programs improved pain and function in knee osteoarthritis patients who were overweight.  While both were beneficial, exercise had a greater effect than die

Telemedicine Upside Interview with Dr. Alvin Wells

In spite of the transformative growth of telemedicine during the COVID-19 pandemic, rheumatologys use of telemedicine is waning, much like the masks that use to be on everyones face.

Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE

It is almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under emergency use authorization (EUA). The question still being asked is whether the vaccine is safe for people with lupus? 

More severe COVID-19 outcomes in African American, Hispanic individuals with SLE

Lupus is a disease that disproportionately affects minorities and patients of color. In the past worse disease activity, severity as well as outcomes have been described in African American and Hispanic patients.

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Abstract Numbers below:

Psoriatic arthritis

Can "Ultra-low" dose Rituximab work for RA?

At day 3 of ACR Convergence 2021, the REDO trial presented data in abstract 1443 in an oral presentation challenging how low we can go with rituximab for rheumatoid art

Day 4 Report from ACR21

My favorite three presentations from day 4 at ACR 2021 included the following:

Breakthrough Infections in Rheumatic Disease Patients

ACR21 – Day 3 Report

Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites:

Secukinumab Efficacy in Enthesitis-Related and Juvenile Psoriatic Arthritis.

ACR21 Best Abstracts We Saw - Day 3 (Monday)

The third day of ACR 2021 took a big leap in online content.  Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty. 

ACR21 Best Abstracts - Day 2

The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).

ACR21 Best Abstracts - Day 1

The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.

Opening Day Report

The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).

Social

#ACR22 Year in Review. Dr Langford summarised significant progress attained in 2022 in combating #COVID and protect our immunosuppressed patients @RheumNow https://t.co/lZSDRj3bkm
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 years ago
Study showing Evusheld can protect our patients who are immunosuppressed; it saved alot of live. One of Dr. C Langford's pick for #YearinReview @rheumnow #ACR22 https://t.co/6ekWvA6Ruw

TheDaoIndex @KDAO2011 ( View Tweet )

2 years ago
Was delighted to be a (very) small part of the fantastic work by the covid GRA getting a special mention by Dr Langford at yr in review #ACR22 @RheumNow Congrats @RichardPAConway @EBRheum @jeffsparks @SattuiSEMD @rheum_cat 🎉 https://t.co/W0n7rW9pma
Patricia Harkins @DrTrishHarkins ( View Tweet )
2 years ago
Does #COVID19 #vaccine work in #psoriaticarthritis? @RheumNow #ACR22 Abstract #0389 🤚 HR for infection and hospitalization similar between controls and PsA after 2nd vaccination 🤚#Enbrel (OR 2.39) and #JAKi (OR 9.90) higher risk of infection and hospitalization

Catherine Sims, MD @DrCassySims ( View Tweet )

2 years ago
FDA issues an Emergency Use Authorization (EUA) for anakinra (Kineret) to treat Hospitalized COVID-19+ Patients with pneumonia requiring supplemental O2 & ! risk for respiratory failure or increased suPAR levels https://t.co/t5gFULIhCH

Dr. John Cush @RheumNow ( View Tweet )

2 years ago
12 pts w/ new onset IgA vasculitis (IgAV) post COVID- 19 vaccination (5F; age 52 yrs) - 10 had mRNA & 2 viral vector Vax. Time from Vax to Sxs=11.5 d; 8/12 had vasculitis w/ 1st dose; all skin (7 Jts, 4GI, 2 renal). All Rx w/ steroids https://t.co/eCcUkGeAwV https://t.co/VU1LwFxITC
Dr. John Cush @RheumNow ( View Tweet )
2 years ago
NY Times reports preprint article showing that taking Paxlovid w/in 5 days of COVID Test+ lowers risk of Long COVID Sxs by 26%. EMR study of 56,340 COVID pts w/ >= risk factor for severe infx; 9,217 Rx w/ Paxlovid had lesss post-Covid Sxs > 90D https://t.co/JyWEoJbUc7 https://t.co/xvTVNugwhJ
Dr. John Cush @RheumNow ( View Tweet )
2 years ago
The spike protein of SARS-CoV-2 drives NLRP3 inflammasome activation (one of several reasons that patient may flare or activate after COVID-19 infection or vaccination?) https://t.co/92Z14bYaUD https://t.co/iEUSgPghtT
Dr. John Cush @RheumNow ( View Tweet )
2 years ago
Pre and post-COVID-19 assessment of 78 FM pts by Fibromyalgia Impact Questionnaire-Revised (FIQR). While COVID affected FM pts, there was no statistically significant change in FIQR scores (65% had no improvement or deterioration on FIQR) https://t.co/S1clBCvzWm https://t.co/ZApmgvKM2c
Dr. John Cush @RheumNow ( View Tweet )
2 years 1 month ago
1915 Rheumatic (RMD)pts w/ COVID (42% RA. 15% SLE, 1/2 comorbidities); Outcomes: 28% hospitalized, 8% to ICU & 4% died from COVID-19. Poor COVID-19 outcomes seen w/ age, male, Hi Dz activity, steroids & RTX, & 1+ comorbidity https://t.co/ztBiJc9nxV https://t.co/RVOKyjseFJ
Dr. John Cush @RheumNow ( View Tweet )
2 years 1 month ago
×